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The VP3 gene of Chicken Anemia Virus has the potential to be an effective anti-
cancer therapy.  In vitro studies showed that several types of transformed cells 
transfected with recombinant VP3 genes become apoptotic within 72 hours post-
transfection.  The apoptotic activities were confirmed by TUNEL assay, and the 
apoptotic activities were mainly found in the nuclei of transfected cells.  Expression 
of VP3 gene also triggered apoptosis in tumour mass in immune-competent mice. 
Following an injection of 100µg recombinant plasmid containing the VP3 gene into 
a tumour mass, the tumour tissue started to regress from 47.9 ± 5.2 mm3 on day-1 to 
0.8 ± 0.4 mm3 on day-11 post-injection and completely resolved by day-13 post-
injection.  Meanwhile, in control group, the tumour mass measured 54.1 ± 5.2 mm3 
(day-1), increased to 589.0 ± 0.4 mm3 on day-11 post-injection and 808.8 ± 0.4 mm3 
by day-13 post-injection.  In a different experiment, selected cellular (pVIVO-
IL12/GM-CSF) or humoral (pBoost/IL4/IL13) immune modulator was injected 
together with the recombinant plasmid containing VP3 gene.  In the presence of 
cellular immune modulator, the tumour sizes were significantly decreased from 48.6 
± 7.7 mm3 on day-1 post-injection to 0.6 ± 0.4 mm3 on day-9 post injection.  The 
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tumour mass was totally resolved by day-11 post-injection.  The most rapid and 
complete regression of tumour mass as determined on day-11 post-injection, 
suggested that an enhanced effect of tumour regression is attributable to the effect of 
IL12 and GM-CSF.  A delay in tumour growth was also noticed in the treatment 
group receiving a single dose of pVIVO-IL12/GM-CSF plasmid only (100 µg/mouse).  
It is suggested that the anti-cancer mechanism is being induced following expression 
of IL12 gene in the tumor cells.  This in turn will activate Th1 and NK cells.  
Meanwhile, an expression of GM-CSF will cause mobilization of granulocytes and 
macrophages.  Combination of these cellular activities may produce more antigen 
presenting cells for the recognition of tumour-associated antigens that facilitate 
elimination of tumour cells.   The treatment group receiving humoral immune 
modulating factors (IL4/IL13) in addition to VP3 gene therapy showed reduction in 
the size of tumour from 48.5 ± 5.3 mm3 on day-1 post-injection to 4.1 ± 1.6 mm3 on 
day-9 post-injection.  The tumour was totally resolved by day-11 post-injection.  
However, its anti-cancer effect was still mediocre compared to VP3 gene therapy 
incorporated with IL12/GM-CSF.  The flow cytometry analysis on the clusters of 
differentiation (CD) for the 3 treatment groups (Group 1: recombinant VP3 gene 
only; Group 2: recombinant VP3 gene + cellular immune modulator; and Group 3: 
recombinant VP3 + humoral immune modulator) further supported the rationale of 
choosing the particular cellular and humoral immune modulators for effective anti-
cancer therapy.  The percentage of CD4 cells detected in the thymus of tumour –
bearing mice showed that cellular and humoral immune modulators enhanced the 
proliferation of CD4 lymphocyte population in the thymus.  Meanwhile, the highest 
percentage of CD8 count was most distinguished in group 2 (39.02%) on day-10 
post-injection.  An increase in CD8 cell count was probably due to the enhanced 
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immune-stimulation by IL12 and GMCSF expressed by pVIVO-IL12/GM-CSF 
recombinant plasmids against tumour antigens.  The distribution of CD4 and CD8 
lymphocyte populations in the spleen of treated mice has a similar trend as in 
primary lymphoid organs (thymus).  Again, the percentage of CD8 count was most 
distinguished in group 2 (38.00%) on day-10 post-injection.  It is suggested that, the 
increase in CD8 cell counts could be due to the increase in mature cytotoxic T-cells 
produced by the thymus against tumour antigens, as a result of immune-stimulation 
of GM-CSF.  These CD4 and CD8 cells may then be detected in the secondary 
lymphoid organs. The percentage of CD19 lymphocyte populations was only 
prominent in Group 3 (26.71%) on day-10 post-injection. This suggests that the 
increase of CD19 lymphocytes was due to the immune-stimulation by IL4/IL13.  In 
conclusion, recombinant VP3 gene is best combined with cellular immune 
modulators (IL12/GM-CSF) for a more effective anti-cancer gene therapy.  
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Gen VP3 yang berasal daripada virus anemia ayam menpunyai potensi sebagai terapi 
anti-barah yang berkesan.  Kajian in vitro menunjukkan bahawa pelbagai jenis sel 
terubah yang ditransfeksi dengan gen VP3 menjadi apoptotik dalam masa 72 jam 
pasca-transfeksi.  Aktiviti apoptosis ini telah disahkan dengan ujian TUNEL, di 
mana kebanyakkan aktiviti apoptosis telah dikesan di dalam nukleus sel barah.  
Ekspresi gen VP3 juga memicu apoptosis dalam tumbuhan barah pada mencit yang 
berimun kompeten.  Berikutan dengan suntikan 100 µg plasmid rekombinan yang 
mengandungi gen VP3 pada tumbuhan barah, tisu barah mula mengecil daripada 
47.9 ± 5.2 mm3 pada hari pertama pasca-suntikan, sehinggalah 0.8 ± 0.4 mm3 pada 
hari ke-11 pasca-suntikan.  Tumbuhan barah lesap pada hari ke-13 pasca-suntikan.  
Manakala untuk kumpulan kawalan, tumbuhan barah berukur 54.1 ± 5.2 mm3 pada 
hari pertama pasca-suntikan, 589.0 ± 0.4 mm3 pada hari ke-11 pasca-suntikan, 
sehinggalah 808.8 ± 0.4 mm3 pada hari ke-13 pasca-suntikan.  Dalam satu lagi kajian, 
modulator imun sellular (pVIVO-IL12/GM-CSF) atau modulator humoral (pBoost-
IL4/IL13) yang terpilih telah disuntik bersama-sama dengan plasmid rekombinan 
yang mengandungi gen VP3.  Dengan kewujudan modulator imun sellular, saiz 
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tumbuhan barah mengecil dari 48.6 ± 7.7 mm3 pada hari pertama pasca-suntikan, 
sehinggalah 0.6 ± 0.4 mm3 pada hari ke-9 pasca-suntikan.  Tumbuhan barah lesap 
pada hari ke-11 pasca-suntikan.  Kadar pengecilan tumbuhan yang paling cepat dan 
pelesapan tumbuhan barah pada hari ke-11 pasca-suntikan mencadangkan bahawa 
peningkatan kadar regresi tumbuhan barah adalah akibat daripada IL12 dan GM-CSF.  
Penangguhan tumbesaran tumbuhan barah juga diperhatikan dalam kumpulan 
rawatan yang menerima dos tunggal pVIVO-IL12/GM-CSF plasmid (100 µg/mencit).  
Ini mencadangkan bahawa, mekanisme anti-barah telah diaktifan berikutan ekpresi 
gen IL12 dalam sel barah yang mengaktifkan sel Th1 dan NK manakala ekpresi GM-
CSF akan menyebabkan mobilisasi sel granulosit dan makrofaj untuk menghasilkan 
lebih banyak sel persembahan antigen untuk pengenalpastian antigen barah, dan 
seterusnya membantu pembasmian sel barah.  Kumpulan rawatan yang menerima 
suntikan modulator humoral (IL4/IL13) menunjukkan pengecilan size tumbuhan 
barah dari 48.5 ± 5.3 mm3 pada hari pertama sehinggalah 4.1 ± 1.6 mm3 pada hari ke-
9 pasca-suntikan.  Tumbuhan barah lesap pada hari ke-11 pasca-suntikan.  Akan 
tetapi, keberkesanan anti-barah adalah tidak sebaik jika dibandingkan dengan terapi 
gen VP3 dengan gabungan IL12/GM-CSF.  Analisa aliran sitometri terhadap 
kelompok pembezaan (CD) terhadap ketiga-tiga kumpulan rawatan (kumpulan 1= 
gen VP3 sahaja; Kumpulan 2: gen VP3 + pVIVO-IL12/GM-CSF, dan Kumpulan 3: 
gen VP3 + pBoost-IL4/IL13) selanjutnya menyokong rasional pemilihan modulator-
modulator imun tersebut, untuk terapi anti-barah yang berkesan.  Peratus sel CD4 
yang dikesan dalam timus pada mencit yang berbarah menunjukkan bahawa 
modulator sellular dan humoral telah meningkatkan penyebaran populasi limfosit 
CD4.  Manakala, peningkatan peratus sel CD8 adalah paling ketara dalam kumpulan 
2 (39.02%) pada hari ke-10 selepas suntikan.  Peningkatan dalam jumlah sel CD8 ini 
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dipercayai atas stimulasi imun oleh IL12 dan GM-CSF, hasil daripada ekspresi 
plasmid pVIVO-IL12/GM-CSF terhadap antigen barah.  Corak taburan populasi 
limfosit CD4 dan CD8 dalam limpa adalah serupa dalam timus.  Peningkatan 
populasi sel CD8 adalah paling ketara dalam kumpulan 2 (38.00%) pada hari ke-10 
pasca-suntikan. Ini mencadangkan bahawa peningkatan jumlah sel CD8 mungkin 
disebabkan oleh peningkatan populasi CD8 yang matang yang dihasilkan oleh timus 
terhadap antigen barah, hasil daripada stimulasi imun oleh GM-CSF.  Sel-sel CD4 
dan CD8 ini boeh dikesan dalam organ limfoid sekunder.  Peningkatan peratus 
limfosit CD19 hanya ketara dalam kumpulan 3 (26.71%).  Ini mencadangkan 
bahawa penigkatan CD19 adalah disebabkan oleh rangsangan imun IL4 dan IL13, 
hasil daripada suntikan pBoost-IL4/IL13.  Kesimpulannya, terapi gen menggunakan 
gen VP3 dan pVIVO-IL12/GM-CSF merupakan kombinasi terbaik dan paling 
berkesan dalam terapi gen anti-barah.  
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The complete nucleotide sequence of VP3 gene, and its deduced amino 
acid sequence. 
 
3.9 Pairwise alignment for currently used VP3 gene and VP3 gene               59 
derived from CUX-1 strain Chicken Anemia Virus.  The homolgy  
was 96.9%. 
 
3.10 Rounding up of CT26 cells transfected with pcDNA3.1/CT-VP3-              60 
GFP-TOPO, 72 hours post-transfection. (100X magnification) 
 
3.11 CT26 Cells transfected with empty pCMV/myc/nuc,  72 Hours                  61 
 post-transfection. (400X manigfication) 
 
3.12 CT26 transfected with recombinant pcDNA3.1/CT-VP3-              62 
GFP-TOPO plasmids, 72 hours post-transfection.  The VP3-GFP   
fusion proteins were found in the nucleus of CT26 cells, under UV 
translumination. (Top: 100X and Bottom: 400X Magnification) 
 
3.13 CT26 Cells transfected with empty pCMV/myc/nuc plasmids,              62 
72 hours post-transfection. Only the silhouette of CT26 cells was  
seen under UV translumination. (100X magnification) 
 
3.14 Immumoperoxidase test for CT26 transfected with recombinant                 63 
pcDNA3.1/CT-VP3-GFP-TOPO plasmids, 72 hours post-transfection.   
The VP3 proteins were stained brown and found in the nuclei of  
CT26 cells. (100X magnification) 
 
3.15 Immonoperoxidase test for CT26 cells transfected with empty                    63 
pCMV/myc/nuc plasmids, 72 hours post-transfection. (400X  
magnification) 
 
3.16 Immumoperoxidase test for CT26 cells transfected with              64 
recombinant pCMV/myc/nuc-VP3 plasmids, 72 hours post- 
transfection.  The VP3 proteins were stained brown and found in  
the nucleus of CT26 cells. (100X magnification) 
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3.17 Immonoperoxidase test for CT26 cells transfected with empty                    64 
pCMV/myc/nuc plasmids, 72 hours post-transfection. (400X  
magnification) 
 
3.18 DeadEnd Tunel assay for PT67 cells transfected with recombinant             65 
pCMV/myc/nuc-VP3, 72 hours post-transfection. Apoptotic cells  
stained brown in color. (100X magnification) 
 
3.19 DeadEnd Tunel assay for PT67 cells transfected with recombinant             66 
pCMV/myc/cyto-VP3, 72 hours post-transfection. Apoptotic cells  
stained brown in Color. (100X magnificaiton) 
 
3.20 DeadEnd Tunel assay for CT26 Cells transfected with recombinant           66 
pcDNA3.1/CT-VP3-GFP-TOPO plasmids,72 hours post-transfection. 
Apoptotic cells stained brown in color. (100X magnification) 
 
3.21 DeadEnd Tunel assay for CT26 cells transfected with empty             67 
pCMV/myc/nuc plasmids, 72 hours post-transfection.  
No apoptosis detected. (400X magnification) 
 
3.22 DeadEnd Tunel assay for CT26 cells transfected with recombinant            67  
pCMV/myc/nuc-VP3, 72 hours post-transfection. Apoptotic cells  
stained brown in colour. (100X magnification) 
 
3.23 DeadEnd Tunel assay for CT26 cells transfected with recombinant            68 
pCMV/myc/cyto-VP3, 72 hours post-transfection. Apoptotic cells 
stained brown in colour. (400X magnification) 
 
3.24 DeadEnd Tunel assay for CT26 cells transfected with recombinant            68 
pVP22/myc/His-VP3, 72 hours post-transfection. Apoptotic cells  
stained brown in colour. (100X magnification) 
 
3.25 DeadEnd Tunel assay for CT26 cells transfected with empty                      69 
pCMV/myc/nuc plasmids, 72 hours post-transfection. No apoptosis  
detected. (100X magnificaiton) 
 
3.26 DeadEnd Tunel assay for BHK cells transfected with recombinant             69 
pCMV/myc/cyto-VP3, 72 hours post-transfection. Apoptotic cells  
stained brown in colour. (100X magnification) 
 
3.27 DeadEnd Tunel assay for BHK cells transfected with empty                       70 
pCMV/myc/cyto plasmids, 72 hours post-transfection. (400X).  No 
apoptosis detected. (100X magnification) 
 
4.1 Restraining of a mouse.                             80 
 
4.2 The simplified methodology for large scale plasmid preparation.             82 
 
4.3 Intratumour injection of treatment solution using Hamilton syringe.            85 
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4.4 A group of pups with dam. (5-day old)                                          88 
 
4.5 Sexing based on ano-genital distance in a mouse. (Female)                         89 
 
4.6 Measurement of tumor size at the flank region of a mouse, using                 90 
Vernier caliper.  Tumour mass in control group treated with 100 µl  
PBS measured 541.2 ± 62.2mm3 on week-4 post-inoculation of  
CT26 cells. 
 
4.7 Tumour growth for control group of mice.                91 
 
4.8 Tumour mass at the flank region of Balb/c mice induced with CT26   91 
cells.  A: Day-21 post-inoculation (48.9 ± 3.7mm3).  B: Day-63  
post-inoculation (23015.6 ± 2180.9 mm3). 
 
4.9 Tumour mass extended into the hind limb region. The tumour mass       92 
causes difficulties in movement.. 
 
4.10 Measuring of the skin thickness of a mouse.  The skin recorded a                93 
relatively uniform thickness of 0.5 mm for the mice aged 9 weeks  
to 12 weeks. 
 
4.11 Tumour volume in treatment and control group.  The tumour volume 94 
started to regress after the injection of recombinant pcDNA3.1/VP3-CT 
-GFP-TOPO plasmid solution.  The tumour mass for control group  
continued to grow in an exponential pattern. 
 
4.12 Tumour regression after the injection of recombinant pcDNA3.1/             94 
VP3-CT-GFP-TOPO plasmid solution.  LEFT: Day-9 post-injection,  
tumour volume= 14.5 ± 2.9 mm3.  RIGHT: Day-11 post-injection,  
tumour volume= 1.5 ± 0.4 mm3. 
 
4.13 Tumor mass induced by 106 CT26 cells in a group of mouse.              95 
A: Tumour mass attached to the subcutaneous tissue. B: Closed-up  
view for the detached mass.  C: Several tumour masses detached 
from the subcutaneous region in a group of mice, 7 weeks post-
inoculation of CT26 cells . 
 
4.14 An atrophied mouse, 50 days post-inoculation with CT26 cells.  The               96 
tumour was 35 x 20 mm2, measuring approximately 7000 ± 398 mm3  
in volume.  LEFT: Legs, backbone, and ribs were atrophic.  RIGHT: 
Vascularization of tumour mass. 
 
4.15 Gross examination of  the internal organs of mice treated with            97 
recombinant pcDNA3.1/VP3-CT-GFP-TOPO plasmids, 2 weeks post-
treatment. A= An overview of internal organs; B=Liver and spleen,  
C=Spleen cut surface; D= Reproductive tract; E=Gastro-intestinal tract, 
F=Kidney cut surface. 
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4.16 Histology of tumour mass injected with recombinant pcDNA3.1/VP3-         98 
CT -GFP-TOPO Plasmids.  TOP: Day-1 post-injection.  Normal CT26  
cells.  BOTTOM: Day-3 post-injection.  CT26 cells with condensed nuclei  
were seen in 30% of 5 microscopic fields. (400X magnification).  H&E 
 staining. 
 
4.17 Histology of tumour mass injected with recombinant pcDNA3.1/                 99 
VP3-CT-GFP-TOPO Plasmids, day-5 post-injection.  TOP: CT26 cells  
with condensed nuclei were seen in approximately 70% microscopic  
field (200X magnification). H&E staining.  BOTTOM: CT26 cells with 
condensed nuclei were tested positive for apoptosis using TUNEL assay 
(1000X magnification). 
4.18 Histology of tumour mass injected with recombinant pcDNA3.1/               100 
VP3-CT-GFP-TOPO plasmids, Day-7 post-injection.  CT26 cells with 
 condensed nuclei were seen in approximately 95% of microscopic field.   
 (400X magnification). H&E staining. 
 
4.19 Histology of tumour mass, day-1, -3 and -5 post-injection with 100µl         100 
phosphate buffer saline CT26 cells were distributed evenly and  
microvessels are observed, indicating the early phase of angiogenic  
process. (400X magnification).  H&E staining. 
 
4.20 Histology of tumour mass, 3 weeks post-inoculation of CT26                     101 
cells.  Microvessels established in between the CT26 cells  
(400X magnification).  H&E staining. 
 
4.21 Histology of tumour mass, 4 and 5 weeks post-inoculation of CT26            103 
cells.  A: An established vasculature was seen in tumour mass 4 weeks  
post-inoculation of CT26 cells.  Each blood vessel was composed  
of approximately 14-16 endothelial cells (400X magnification). B: More 
widely distributed vasculature was noticed, with the blood vessel  
composed of approximately 28-30 endothelial cells, 5 weeks post- 
inoculation with CT26 (400X magnification).  C: A closed-up view  
for tumour induced by CT26 cells, showing the congested blood vessels, 
5 weeks post-inoculation (1000X magnification).  H&E staining. 
 
4.22 Histology of tumour mass, 6 and 7 weeks post-inoculation of  CT26           104 
cells.  A: Infiltration of lymphocytes was seen in about 25% of area  
under the microscopic field, 6 weeks post-inoculation of CT26 cells  
(200X magnification).  B: Closed-Up view for infiltrated lymphocytes.   
Some of the mitotic figures of CT26 cells were noticed too (1000X 
magnification).  C: The number of infiltrated lymphocytes was  
distributed more widely, and mixed with the necrotic CT26 cells  
(200X magnification).  D: Cell debris was also found among the CT26  
cells and lymphocytes,indicating the initiation of necrotic process  
(1000X magnification).  H&E Staining.  
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4.23 Histology of tumour mass, 8 and 9 weeks post-inoculation of                      105 
CT26 cells.  A: A mixture of necrotic cells and lymphocytes was  
seen distributed among the CT26 cells, more lymphocytes were  
noticed near to the vasculatures, 8 weeks post-inoculation with  
CT26 cells.  The vasculature was congested (200X magnification).   
B: The rampant congested vasculature was seen in most of the  
microscopic field, together with the mixture of necrotic cells  
and infiltrated lymphocytes, 9 weeks post-inoculation of CT26 cells  
(200X magnification).  C: Closed-up view showed the mixture of 
 lymphocytes and necrotic cells with their debris (1000X magnification).  
 
5.1 Physical map of expected recombinant pVIVO-IL12/GM-CSF.           113 
 
5.2 Experimental layout for the detection of IL12 and GM-CSF protein             121 
using immunoassay.  High= 500 pg/mL of IL12 or GM-CSF protein;  
standard 1 to 6 = 2 fold dilution of high standards, Samples:  
supernatant containing IL12 and GM-CSF proteins; Control =  
supernatant from CT26 cells transfected with empty pVIVO vector. 
  
5.3 PCR amplification of IL12 and GM-CSF genes from a commercial      123 
source (Invivogen) using two sets of primers designed. LEFT:  
Lane 1: IL12 gene amplification using forward and reverse primers  
designed. Gene band sized approximately 1600 bp.  M= 1 kb ladder  
marker.  RIGHT: GM-CSF gene amplification using forward and reverse 
primers designed. Gene band sized approximately 550 bp.  M= 100 bp  
ladder marker. 
 
5.4 Double restriction of recombinant pVIVO-IL12/GM-CSF plasmid       124 
confirmed the presence of IL12 and GM-CSF gene inserts in the  
vector. LEFT: Lane 1: Linearalized pVIVO-GMCSF vector sized 
approximately 5.1 kbp with the presence of IL12 gene at  
approximately 1600 bp.  RIGHT: Lane 1: Linearalized pVIVO-IL12 
vector sized approximately 6.2kbp with the presence of GM-CSF  
Gene at approximately 550 bp.  (M= 1 kb Ladder Marker) 
 
5.5 In-frame GMCSF gene amplified from pVIVO-IL12/GM-CSF       125 
plasmids, with complete nucleotide sequence and its deduced  
amino acids.  DNA sequencing result was analyzed by BioEdit 
software package. 
 
5.6 In-frame IL12 gene amplified from pVIVO-IL12/ GM-CSF           126 
plasmids, with complete nucleotide sequence and its deduced  
amino acids.  DNA sequencing result was analyzed by BioEdit 
software package. 
 
5.7 Standard curve for IL12 protein concentration.             127 
 
5.8 Standard curve for GM-CSF protein concentration.             127 
 
 
